The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy.

The randomized, double-blind, placebo-controlled MODEL trial (ClinicalTrials.gov Identifier: NCT05516992) evaluated the safety and efficacy of SB-01 in 417 adults with CLBP and related disability due ...

CMTX-101 is an investigational immune-enabling antibody designed to target and destroy the pro-inflammatory structure of bacteria biofilms.

Proportion of treated women began to decline 18 months before childbirth, reaching 27.9% at the estimated time of conception.

HealthDay News — People with eating disorders report success with self-medicating with nonprescribed drugs instead of prescription antidepressants, according to a study published online July 22 in ...

David Holtzman, a retired privacy expert, said much of the technology already exists and that past federal efforts to set up similar systems “have proven to be ineffective." ...

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

Participants did not have islet autoantibodies and had significantly lower median type 1 diabetes genetic risk score.

Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis.

The SetPoint System consists of a neurostimulation device that is surgically placed under general anesthesia on the vagus ...

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in ...